The last two decades have seen often limited treatment options for cancers give way to therapies with increasingly complex and targeted mechanisms of action as understanding of the disease
Verily, the life sciences company owned by Google parent Alphabet, has teamed up with Novartis, Sanofi, Otsuka, and Pfizer on a project that aims to speed up clinical trials.
Over the years, many hands have been wrung over clinical trial recruitment – low participation rates are common and can bring down studies before they even get a chance to begin.